
Johnson & Johnson's JNJ.N shares are down ~1% to $155.45 on Tues ahead of the pharma co's quarterly earnings due on Wed, with analysts expecting modest rev growth
JNJ is on track for three consecutive sessions of losses
Analysts expect JNJ to report rev of ~$22.8 bln, up 1.75% from a year ago, and adj EPS of $2.68 per share, down ~5% from a year ago
JNJ's rev has exceeded analyst expectations 7 times over the last 8 quarters, while adj EPS has surpassed estimates every time in the same period
President Donald Trump said last week that he plans to announce tariffs on imported pharmaceuticals which could reach 200% but that he would give drugmakers about one year "to get their act together"
J&J is up 7.5% YTD versus the S&P 500 health index's .SPXHC 3.5% dip